



**Benevolent<sup>AI</sup>**

## **Radnor Capital working with BenevolentAI**

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods.

BenevolentAI has a consistently proven track record of scientifically validated discoveries. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful collaborations with AstraZeneca, as well as leading 2 research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Radnor is retained by BenevolentAI to provide fully outsourced investor relations advisory ahead of its business combination with Odyssey Acquisition S.A. and upon completion of the transaction (April) as a listed company on the Euronext Amsterdam exchange.